Peptipedia
Weight LossFDA ApprovedFDA Approved

Exenatide

Also known as Byetta, Bydureon, Exendin-4

The first GLP-1 receptor agonist approved for diabetes. Derived from Gila monster saliva. 53% homology with human GLP-1.

FDA Approved - Type 2 diabetes
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

5-10 mcg twice daily or 2 mg weekly

Frequency

Twice daily (IR) or once weekly (ER)

Duration

Long-term / chronic use

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 5-10 mcg twice daily or 2 mg weekly via Subcutaneous injection, Twice daily (IR) or once weekly (ER). Dose range: 5-10 mcg per dose (IR) or 2 mg weekly (ER). Duration: Long-term / chronic use.

Timing & Administration

Administer via Subcutaneous injection. Frequency: Twice daily (IR) or once weekly (ER).

Mechanism of Action

Synthetic version of exendin-4 from Gila monster venom. Resists DPP-4 degradation. Activates GLP-1 receptors to improve glucose control and reduce appetite.

Research Summary

Evidence level: fda approved. Clinical status: FDA Approved - Type 2 diabetes.

Side Effects & Safety

Important Warnings

  • Boxed warning: pancreatitis
Nausea
vomiting
diarrhea
dizziness
hypoglycemia
injection site reactions
pancreatitis
acute kidney injury

References

No references available.

Related Peptides

Browse all →
SemaglutideWeight Loss

A GLP-1 receptor agonist with multiple FDA approvals including weight management, type 2 diabetes treatment, cardiovascular risk reduction, and kidney disease protection. 94% amino acid similarity to human GLP-1.

View profile
TirzepatideWeight Loss

A dual GIP/GLP-1 receptor agonist representing next-generation incretin-based therapy, demonstrating superior weight loss outcomes compared to semaglutide in direct clinical comparisons.

View profile
RetatrutideWeight Loss

A triple agonist activating GLP-1, GIP, and glucagon receptors for enhanced weight loss outcomes.

View profile